

Market Announcement

15 October 2025

Orthocell Limited (ASX: OCC) – Trading Halt

Trading in the securities of Orthocell Limited ('OCC') will be halted at the request of OCC, pending the release of an announcement by OCC.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 17 October 2025; or
- the release of the announcement to the market.

OCC's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

15 October 2025

ASX Compliance
Australian Securities Exchange
Level 40, Central Park
152-158 St George's Terrace
PERTH WA 6000

By email: tradinghaltspert@asx.com.au



Request for Trading Halt

Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") requests that its securities be placed into an immediate trading halt.

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to this request:

- (a) the trading halt is requested pending an announcement by the Company in relation to a proposed capital raising;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company making an announcement in relation to a proposed capital raising and the opening of trading on Friday, 17 October 2025;
- (c) the Company is not aware of any reason why the trading halt should not be granted; and
- (d) the Company is not aware of any other information necessary to inform the market about the trading halt.

Release authorised by the Board of Orthocell Limited.

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD
P: +61 8 9360 2888
E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
H[^]CK Director
P: +61 423 139 163
E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors
P: +61 404 094 384
E: sduffy@vectoradvisors.au

For personal use only

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 15 US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand and Canada. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

For personal use only